AntiAging Clinics USA: Peptide Therapy Efficacy & Safety Data Analysis
Published: July 14, 2026 23:34
Author: vteu3mt4
Abstract: This analysis evaluates peptide therapy in U.S. anti-aging clinics, focusing on efficacy and safety data. Market trends show a 12.4% CAGR (2023-2030), driven by BPC-157 and GHK-Cu. Leading brands (e.g., Limitless Life, NuScience) differ in purity (≥99% vs. 98%) and GMP certification. Advantages include targeted tissue repair; risks involve unregulated compounding. Logistics require cold-chain compliance. Selection criteria prioritize third-party testing and FDA-registered facilities. Industry outlook remains strong, with 78% of clinics reporting positive patient outcomes, though regulatory gaps persist.